AXIM BiotechnologiesAXIM Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2025. The stock has 7 warning signs investors should review. Among 1,205 Biotechnology companies, AXIM Biotechnologies ranks better than 99.92% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AXIM Biotechnologies's annualized net income for the quarter that ended in Jun. 2025 was $1.48 Mil. AXIM Biotechnologies's average shareholder tangible equity for the quarter that ended in Jun. 2025 was $-13.58 Mil. Therefore, AXIM Biotechnologies's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2025 was Negative Tangible Equity%.
The historical rank and industry rank for AXIM Biotechnologies's Return-on-Tangible-Equity or its related term are showing as below:
AXIM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: Negative Tangible Equity
AXIM's Return-on-Tangible-Equity is ranked better than 99.92% of 1205
companies
in the Biotechnology industry
Industry Median: -42.47
vs AXIM: Negative Tangible Equity
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
AXIM Biotechnologies Return-on-Tangible-Equity Related Terms
AXIM Biotechnologies Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM vs HEPA, SCNI, BZYR: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, AXIM Biotechnologies's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of Negative Tangible Equity% mean?
AXIM Biotechnologies (AXIM) has a Return-on-Tangible-Equity of Negative Tangible Equity% as of Jun. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AXIM Biotechnologies and its competitors. According to the industry distribution chart, AXIM Biotechnologies ranks #1 out of 1205 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.
Is AXIM Biotechnologies' Return-on-Tangible-Equity too high?
AXIM Biotechnologies' current Return-on-Tangible-Equity is Negative Tangible Equity%. Based on the distribution chart, AXIM Biotechnologies ranks #1 out of 1205 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does AXIM Biotechnologies' Return-on-Tangible-Equity compare to HEPA and SCNI?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #1 out of 1205 companies for Return-on-Tangible-Equity. This places AXIM Biotechnologies in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Return-on-Tangible-Equity is Negative Tangible Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Return-on-Tangible-Equity of Negative Tangible Equity%. The current Return-on-Tangible-Equity is Negative Tangible Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Return-on-Tangible-Equity is Negative Tangible Equity% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 